Review Article
Autophagic and Apoptotic Effects of HDAC Inhibitors on Cancer Cells
Table 1
Characteristics of HDAC inhibitors in clinical trials.
| Chemistry | Compounds | HDAC Targets | Clinical trials | Ref |
| Hydroxymates | SAHA (vorinostat) | Classes I, II, and IV | Phase III* | [6] | PXD101 (belinostat) | Classes I, and IIa, HDAC6 | Phase II | [7] | Trichostatin A | Classes I and II | Toxic | [8] | LAQ824 (dacinostat) | Classes I and II | Phase I | [9] | PCI24781 | Classes I and IIb | Phase I | [10] | LBH589 (panobinostat) | Classes I and IIa | Phase II | [11] |
| Cyclic tetrapeptides | FK228 (romidepsin) | HDAC1, 2, 4, 6 | Phase II | [12] |
| Benzamides | MGCD0103 (mocetinostat) | HDAC1, 2, 3, 11 | Phase II | [13] | MS275 (entinostat) | HDAC1, 2, 3, 9 | Phase II | [14] |
| Short-chain fatty acids | Valproic acid | Classes I and IIa | Phase II | [15] | Butyrate | Classes I and IIa | Phase II | [16] |
|
|
*Approved (cutaneous T-cell lymphoma).
|